Dr. Vacirca studies the effects of various treatments on patients undergoing chemotherapy and those suffering from specific cancers such as pancreatic and prostate cancer. He has conducted significant research on anti-nausea medications, seeking to determine which treatment can minimize healthcare costs while effectively managing chemotherapy-induced nausea and vomiting. In addition, he investigates how targeting certain proteins in cancer cells can enhance the body’s immune response, ultimately aiming to find better therapies for patients with hard-to-treat cancers.
Key findings
Patients on injectable granisetron during chemotherapy had an average hydration cost of $296, compared to $837 for those on palonosetron, saving over $500 per patient.
In studies of pancreatic cancer, blocking the PD-1 protein led to tumor shrinkage in 67% of cases, indicating a promising treatment path.
Men treated with the immunotherapy sipuleucel-T for metastatic castration-resistant prostate cancer had a median survival of 30.7 months.
Patients starting treatment for metastatic pancreatic cancer reported a significant reduction in pain scores, from an average of 47.1 to 27.6 overall pain.
Granisetron extended-release led to patients requiring only 0.3 liters of extra hydration versus 0.9 liters for those on palonosetron, suggesting better hydration management.
Frequently asked questions
Does Dr. Vacirca study chemotherapy-induced nausea?
Yes, he studies how different anti-nausea medications can reduce costs and improve symptom management for patients undergoing chemotherapy.
What treatments has Dr. Vacirca researched for pancreatic cancer?
He has researched targeting the PD-1 protein to enhance immune response against pancreatic cancer cell growth.
Is Dr. Vacirca's work relevant to prostate cancer patients?
Yes, he has studied the effectiveness of immunotherapy treatments for men with metastatic castration-resistant prostate cancer.
What impact does early treatment have on pancreatic cancer patients?
His research shows that starting treatment can significantly reduce pain for patients with metastatic pancreatic cancer.
How do Dr. Vacirca's findings affect healthcare costs for cancer treatments?
His studies indicate that using certain treatments can lead to substantial savings, such as over $500 per patient in hydration costs during chemotherapy.
Publications in plain English
Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
2021
American health & drug benefits
Barnes M, Calcanes G, Mosier MC, Vacirca J, Malik Z
Plain English This study compared two treatments for preventing nausea and vomiting caused by chemotherapy: a new under-the-skin injection called granisetron and an intravenous treatment called palonosetron. Researchers looked at medical records of 182 patients and found that those using granisetron spent an average of $296 on unscheduled hydration due to nausea, while those on palonosetron spent $837, showing a significant savings with granisetron. This matters because it suggests that granisetron can help reduce healthcare costs while effectively managing nausea and vomiting for chemotherapy patients.
Who this helps: Patients undergoing chemotherapy.
Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
2021
American health & drug benefits
Barnes M, Calcanes G, Mosier MC, Vacirca J, Malik Z
Plain English This study compared two anti-nausea drugs—granisetron given as an injection and palonosetron given by infusion—to see which one led to lower costs for patients needing extra hydration due to chemotherapy-induced nausea and vomiting. Researchers found that patients receiving the injectable granisetron had an average hydration cost of $296, while those on palonosetron paid about $837, saving over $500 per patient. This is important because it shows that using granisetron can significantly reduce unnecessary healthcare expenses for patients undergoing chemotherapy.
Who this helps: Patients undergoing chemotherapy who suffer from nausea and vomiting.
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
2020
Cancer
Higano CS, Armstrong AJ, Sartor O, Vogelzang NJ, Kantoff PW +16 more
Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer.
2020
British journal of cancer
Gao M, Lin M, Moffitt RA, Salazar MA, Park J +8 more
Plain English This study looked at the use of a treatment that directly targets a protein called PD-1 in patients with pancreatic cancer, a type of cancer that is often hard to treat. Researchers found that targeting PD-1 can help improve the body's immune response against the cancer cells. This is important because it could lead to better treatment options for patients who currently have limited options.
Who this helps: This helps pancreatic cancer patients.
Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer.
2019
British journal of cancer
Gao M, Lin M, Moffitt RA, Salazar MA, Park J +8 more
Plain English This study looked at how pancreatic cancer cells use a protein called PD-1 to both escape the immune system and promote their own growth. The researchers found that when PD-1 was blocked, the tumors shrank by 67%, and combining new cancer treatments with existing immune therapies led to the best results in lab tests. This matters because it shows a promising path for treating pancreatic cancer more effectively by directly targeting these pathways.
Who this helps: This helps patients with pancreatic cancer and their doctors in developing better treatment options.
Plain English This study looked at the effectiveness of sipuleucel-T, an immunotherapy treatment, for men with a specific type of advanced prostate cancer that is resistant to hormone therapy. They tracked nearly 2,000 patients over a median time of about 3.9 years and found that those treated with sipuleucel-T had a median survival of 30.7 months. Most patients who died, about 77%, passed away due to the progression of their cancer, highlighting the importance of this treatment in managing severe cases.
Who this helps: This research benefits patients with metastatic castration-resistant prostate cancer and their healthcare providers by providing up-to-date survival data for treatment discussions.
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
2018
Future oncology (London, England)
Vacirca J, Caruana D, Calcanes G, Mosier M, Boccia R +1 more
Plain English This study looked at how much extra hydration patients need to prevent nausea and vomiting during chemotherapy when using two different medications: palonosetron and granisetron extended-release. They found that patients using palonosetron needed more hydration, with an average of 0.9 liters compared to just 0.3 liters for those on granisetron. This is important because it suggests that granisetron might help patients stay better hydrated during treatment, which can make the process easier for them.
Who this helps: This benefits patients undergoing chemotherapy.
Health-Related Quality of Life in Patients with Metastatic Pancreatic Cancer.
2017
Journal of gastrointestinal cancer
Picozzi V, Narayanan S, Henry Hu X, Vacirca J
Plain English This study looked at how the quality of life (QoL) differs among patients with metastatic pancreatic cancer at various treatment stages. It found that patients receiving the first-line treatment of nab-paclitaxel plus gemcitabine reported less pain compared to those who hadn’t started treatment, with average pain scores dropping from 47.1 to 27.6 for overall pain and from 45.4 to 27.9 for pancreatic-specific pain. This is important because it highlights that starting treatment can significantly reduce pain and improve the daily life of patients.
Who this helps: This helps patients with metastatic pancreatic cancer by showing the benefits of early treatment.
APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial.
2017
Cancer management and research
Schnadig ID, Agajanian R, Dakhil C, Gabrail N, Vacirca J +7 more
Plain English This study compared two treatments, APF530 and ondansetron, for preventing nausea and vomiting in patients undergoing certain types of chemotherapy that are known to cause severe side effects. It was found that APF530 led to better control of these symptoms after chemotherapy, with patients reporting fewer instances of nausea and needing less rescue medication. This is important because managing nausea and vomiting can significantly improve a patient's quality of life during treatment.
Who this helps: This helps patients undergoing aggressive chemotherapy, especially those receiving anthracycline and cyclophosphamide regimens.
The organomercurial 4-aminophenylmercuric acetate, independent of matrix metalloproteinases, induces dose-dependent activation/inhibition of platelet aggregation.
2005
Thrombosis and haemostasis
Rosenfeldt MT, Valentino M, Labruzzo S, Scudder L, Pavlaki M +4 more
Plain English This study looked at how a chemical called 4-aminophenylmercuric acetate (APMA) affects how blood platelets clump together, which is important for blood clotting. Researchers found that at a low dose of 5 microM, APMA helped platelets stick together, but at higher doses (50 microM or more), it actually stopped them from clumping. This research is significant because understanding how different substances influence platelet behavior can help refine treatments for conditions that involve blood clotting, like heart disease.
Who this helps: This helps patients with heart conditions and doctors treating clotting disorders.
Role of matrix metalloproteinases (MMPs) in colorectal cancer.
2004
Cancer metastasis reviews
Zucker S, Vacirca J
Plain English This study focused on a group of enzymes called matrix metalloproteinases (MMPs) and their role in colorectal cancer. Researchers found that certain MMPs, like MMP-1, -2, -3, and -9, are overproduced in colorectal cancer, with levels often linked to how advanced the cancer is; for instance, higher MMP-3 levels correspond to poorer patient outcomes. Understanding these connections is crucial because it could lead to better-targeted treatments and improved prognoses for patients.
Who this helps: This research benefits patients with colorectal cancer and doctors treating them.